Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 7
  5. Article
Volume 23, Issue 7
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Introduction

The abuse of veterinary drugs has emerged as a concerning trend, with global fatalities on the rise. Our understanding of this phenomenon remains limited. This study aims to identify the veterinary drugs being misused, the reasons behind their misuse, and how they are obtained.

Methods

Utilising PubMed, Scopus, and Web of Science databases, along with related grey literature, we applied the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) framework for data collection. Screening and cross-referencing yielded 66 relevant articles, encompassing case reports, surveys, reports, and systemic literature reviews. The analysis identified 28 distinct veterinary drugs being misused in humans, primarily falling into categories, ., α-2- and β-2-adrenergic receptor agonists, GABAergic receptor modulators, opioid receptor agonists, non-steroidal anti-inflammatory drugs (NSAIDs), and N-methyl-D-aspartate (NMDA) receptor antagonists. These drugs were used for various purposes, including recreational use, weight loss, bodybuilding, pain relief, and self-medication for stress-related symptoms.

Results

Routes of administration predominantly included parenteral, oral, and inhalation methods. Veterinary workers/assistants and individuals connected to animals were identified as contributors to the misuse of these medications. Motivations for their utilisation ranged from affordability and accessibility to the ease of obtaining multiple prescriptions from various veterinary sources, often in conjunction with other illicit substances. Dependence and addiction were common outcomes of the misuse of veterinary medicines by humans.

Conclusion

Overall, this systematic review underscores the increasing popularity of veterinary prescription drug misuse despite being under-reported with limited available data. Healthcare professionals are urged to remain vigilant to potential overdose events involving these medications.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X333443240822115028
2024-09-16
2025-05-18

  • From This Site

    /content/journals/cn/10.2174/011570159X333443240822115028
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SchepisT.S. KlareD.L. FordJ.A. McCabeS.E. Prescription drug misuse: Taking a lifespan perspective.Subst. Abuse202014117822182090935210.1177/1178221820909352 32214819
     [Google Scholar]
  2. WilsonC. Addiction to prescription drugs is UK 'Public Health Disaster'.Available from: https://www.newscientist.com/article/2110089-addiction-to-prescription-drugs-is-uk-publichealth-disaster/ 2016
  3. Prescription Cost Analysis - England - 2022-23.Available from: https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england/prescription-cost-analysis-england-2022-23 2023
  4. PrestonM. The rise in prescription drug addiction.Available from: https://delamere.com/blog/the-rise-in-prescription-drug-addiction 2022
  5. Deaths related to drug poisoning in England and Wales: 2021 registrations.Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2021registrations 2021
  6. AnandA. HosanagarA. Drug misuse in the veterinary setting: An under-recognized avenue.Curr. Psychiatry Rep.2021232310.1007/s11920‑020‑01214‑8 33403403
     [Google Scholar]
  7. LehnusK.S. FordyceP.S. McMillanM.W. Electronic survey investigating UK veterinarians’ perceptions of the potential for veterinary prescription medication misuse or abuse.Vet. Anaesth. Analg.2024511162510.1016/j.vaa.2023.09.004 38065823
     [Google Scholar]
  8. Abuse and Diversion of Controlled Substances: A Guide for Health Professionals.Available from: https://publications.gc.ca/collections/collection_2018/sc-hc/H128-1-06-467-eng.pdf 2018
  9. Illegal Animal Medicines: Seizure and Improvement Notices, Prosecutions and Police Cautions.Available from: https://www.gov.uk/government/collections/illegal-animal-medicines-seizure-and-improvement-notices#notices-published-in-april-2021- 2021
  10. How to Recognize a Vet Shopper.Available from: https://www.avma.org/sites/default/files/2019-11/Opioids_Vet-Shopping-Drug-Diversion_Guide-for-Veterinarians_flyer.pdf 2019
  11. ChuaK.P. PerroneJ. ReddingL.E. BrummettC.M. BahlS. BohnertA.S. Trends in the number of patients linked to potential vet-shopping behavior in the United States (2014-2019).Am. J. Vet. Res.202283214715210.2460/ajvr.21.10.0173 34941568
     [Google Scholar]
  12. Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new resource guide to support responsible opioid prescribing for pain management in animals.Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-fdas-new-resource-guide-support-responsible-opioid
  13. HerzogH. Hurting pets to get attention and drugs: A growing problem.Available from: https://www.psychologytoday.com/gb/blog/animals-and-us/201808/hurting-pets-get-attention-and-drugs-growing-problem 2018
  14. BurkeC.J. Drug Diversion in Veterinary Medicine.Available from: https://www.pharmacytimes.com 2002
  15. Veterinary Clinical Trials - Veterinary Clinical Studies, Veterinary StudiesAnimal Health Consultants.Available from: https://animalhealthconsultants.com/veterinary-clinical-trials/
  16. LeBourgeoisH.W.III ForemanT.A. ThompsonJ.W.Jr Novel cases: Malingering by animal proxy.J. Am. Acad. Psychiatry Law2002304520524 12539907
     [Google Scholar]
  17. CohenJ. Dangers of humans taking animal drugs and vice versa.Available from: https://www.forbes.com/sites/joshuacohen/2024/04/11/dangers-of-humans-taking-animal-drugs-and-vice-versa/ 2024
  18. CorkeryJ.M. HungW.C. ClaridgeH. GoodairC. CopelandC.S. SchifanoF. Recreational ketamine-related deaths notified to the national programme on substance abuse deaths, England, 1997-2019.J. Psychopharmacol.202135111324134810.1177/02698811211021588 34092131
     [Google Scholar]
  19. Drug Misuse in England and Wales - Office for National Statistics.Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/articles/drugmisuseinenglandandwales/yearendingmarch2023 2023
  20. SwansonD.M. HairL.S. Strauch RiversS.R. SmythB.C. BroganS.C. VentosoA.D. VaccaroS.L. PearsonJ.M. Fatalities involving carfentanil and furanyl fentanyl: Two case reports.J. Anal. Toxicol.201741649850210.1093/jat/bkx037 28575422
     [Google Scholar]
  21. ZawilskaJ.B. KuczyńskaK. KosmalW. MarkiewiczK. AdamowiczP. Carfentanil - From an animal anesthetic to a deadly illicit drug.Forensic Sci. Int.202132011071510.1016/j.forsciint.2021.110715 33581655
     [Google Scholar]
  22. MoherD. LiberatiA. TetzlaffJ. AltmanD.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.Ann. Intern. Med.2019151426426910.7326/0003‑4819‑151‑4‑200908180‑00135 19622511
     [Google Scholar]
  23. MoherD. LiberatiA. TetzlaffJ. AltmanD.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.BMJ2009339b253510.1136/bmj.b2535 19622551
     [Google Scholar]
  24. FalagasM.E. PitsouniE.I. MalietzisG.A. PappasG. Comparison of pubmed, scopus, web of science, and google scholar: Strengths and weaknesses.FASEB J.200822233834210.1096/fj.07‑9492LSF 17884971
     [Google Scholar]
  25. Bristol Medical School: Population Health Sciences.Available from: https://www.bristol.ac.uk/media-library/sites/social-community-medicine/robis/ROBIS%201.2%20Clean.pdf 2024
  26. NairA. JacobS. A simple practice guide for dose conversion between animals and human.J. Basic Clin. Pharm.201672273110.4103/0976‑0105.177703 27057123
     [Google Scholar]
  27. AllevaA. WangS. DeMuroJ. HannaA. Phenobarbital toxicity from a highly concentrated veterinary formulation: Review and case report.Crit. Care Shock20151824651
     [Google Scholar]
  28. de la PeñaJ.B. CheongJ.H. The abuse liability of the NMDA receptor antagonist‐benzodiazepine (tiletamine‐zolazepam) combination: Evidence from clinical case reports and preclinical studies.Drug Test. Anal.20168876076710.1002/dta.1987 27341080
     [Google Scholar]
  29. PerrinA.J. Intentional misuse of veterinary medications in human suicide.J. Vet. Pharmacol. Ther.201538320921310.1111/jvp.12184 25404261
     [Google Scholar]
  30. Ruiz-ColónK. Chavez-AriasC. Díaz-AlcaláJ.E. MartínezM.A. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature.Forensic Sci. Int.20142401810.1016/j.forsciint.2014.03.015 24769343
     [Google Scholar]
  31. HoffmannU. MeisterC.M. GolleK. ZschiescheM. Severe intoxication with the veterinary tranquilizer xylazine in humans.J. Anal. Toxicol.200125424524910.1093/jat/25.4.245 11386637
     [Google Scholar]
  32. RussellC. FischerB. FidalgoT.M. Sourcing of opioid analgesics for nonmedical use: Are veterinarians the latest frontier?J. Opioid. Manag.2018142777910.5055/jom.2018.0433 29733092
     [Google Scholar]
  33. GreeneS.A. ThurmonJ.C. Xylazine - a review of its pharmacology and use in veterinary medicine.J. Vet. Pharmacol. Ther.198811429531310.1111/j.1365‑2885.1988.tb00189.x 3062194
     [Google Scholar]
  34. SibbesenJ. AbateM.A. DaiZ. SmithG.S. LundstromE. KranerJ.C. MockA.R. Characteristics of xylazine‐related deaths in West Virginia—Xylazine‐related deaths.Am. J. Addict.202332330931310.1111/ajad.13365 36504413
     [Google Scholar]
  35. Centers for Disease Control and PreventionIllicitly Manufactured Fentanyl-Involved Overdose Deaths with Detected Xylazine - United States, January 2019-June 2022; 2023; pp. 721-727.Available From: https://www.cdc.gov/mmwr/volumes/72/wr/mm7226a4.htm
  36. Acosta-MaresP. Violante-SoriaV. BrowneT.Jr CruzS.L. Xylazine potentiates the lethal but not the rewarding effects of fentanyl in mice.Drug Alcohol Depend.202325311099310.1016/j.drugalcdep.2023.110993 37883846
     [Google Scholar]
  37. Drug Enforcement Administration (DEA)DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine.Available From: https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed- (Accessed on 28th June, 2024).
     [Google Scholar]
  38. RockK.L. LawsonA.J. DuffyJ. MellorA. TrebleR. CopelandC.S. The first drug-related death associated with xylazine use in the UK and Europe.J. Forensic Leg. Med.20239710254210.1016/j.jflm.2023.102542 37236142
     [Google Scholar]
  39. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Drug-induced deaths - the current situation in Europe (European Drug Report 2023).Available From: https://www.emcdda.europa.eu/publications/european-drug-report/2023/drug-induced-deaths_en (Accessed on 28th June, 2024).2023
  40. KacinkoS.L. MohrA.L.A. LoganB.K. BarbieriE.J. Xylazine: pharmacology review and prevalence and drug combinations in forensic toxicology casework.J. Anal. Toxicol.202246891191710.1093/jat/bkac049 35770859
     [Google Scholar]
  41. JohnsonJ. PizzicatoL. JohnsonC. VinerK. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019.Inj. Prev.202127439539810.1136/injuryprev‑2020‑043968 33536231
     [Google Scholar]
  42. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Injecting drug use in Europe - the current situation (European Drug Report 2023).Available From: https://www.emcdda.europa.eu/publications/european-drug-report/2023/injecting-drug-use_en (accessed on 28th June, 2024).EMCDDA 2023
  43. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Other drugs - the current situation in Europe (European Drug Report 2023).Available From: https://www.emcdda.europa.eu/publications/european-drug-report/2023/other- (Accessed on 28th June, 2024).2023
  44. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Harm reduction - the current situation in Europe (European Drug Report 2023).Available From: https://www.emcdda.europa.eu/publications/european-drug-report/2023/harm- (Accessed on 28th June, 2024).2023
  45. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Greater diversity in drug supply and use creates new challenges for Europe.Available From: https://www.emcdda.europa.eu/news/2023/european- (accessed on 11th December, 2023).
  46. ZhuD.T. Public health impact and harm reduction implications of xylazine-involved overdoses: A narrative review.Harm Reduct. J.202320113110.1186/s12954‑023‑00867‑x 37700329
     [Google Scholar]
  47. TeohW.K. MuslimN.Z. ChangK.H. AbdullahA.F.L. Abuse of Xylazine by human and its emerging problems: A review from forensic perspective.Malays. J. Med. Health Sci.2022184190201
     [Google Scholar]
  48. KrongvorakulJ. AuparakkitanonS. TrakulsrichaiS. SanguanwitP. SueajaiJ. NoumjadN. WananukulW. Use of xylazine in drug‐facilitated crimes.J. Forensic Sci.20186341325133010.1111/1556‑4029.13684 29098704
     [Google Scholar]
  49. MooreK.A. RippleM.G. SakinedzadS. LevineB. FowlerD.R. Tissue distribution of xylazine in a suicide by hanging.J. Anal. Toxicol.200327211011210.1093/jat/27.2.110 12670006
     [Google Scholar]
  50. DebnathR. ChawlaP.A. Xylazine addiction turning humans to zombies: Fact or myth?Health Sci. Rev. (Oxf.)2023910013210.1016/j.hsr.2023.100132
     [Google Scholar]
  51. AyubS. ParniaS. PoddarK. BachuA.K. SullivanA. KhanA.M. AhmedS. JainL. Xylazine in the Opioid Epidemic: A systematic review of case reports and clinical implications.Cureus2023153e3686410.7759/cureus.36864 37009344
     [Google Scholar]
  52. FriedmanJ. MonteroF. BourgoisP. WahbiR. DyeD. Goodman-MezaD. ShoverC. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis.Drug Alcohol Depend.202223310938010.1016/j.drugalcdep.2022.109380 35247724
     [Google Scholar]
  53. RubinR. Here’s What to know about Xylazine, aka Tranq, the animal tranquilizer increasingly found in illicit fentanyl samples.JAMA2023329221904190610.1001/jama.2023.8625 37223922
     [Google Scholar]
  54. TorruellaR.A. Xylazine (veterinary sedative) use in Puerto Rico.Subst. Abuse Treat. Prev. Policy201161710.1186/1747‑597X‑6‑7 21481268
     [Google Scholar]
  55. de CarvalhoL.L. NishimuraL.T. BorgesL.P.B. CerejoS.A. VillelaI.O.J. AuckburallyA. de Mattos-JuniorE. Sedative and cardiopulmonary effects of xylazine alone or in combination with methadone, morphine or tramadol in sheep.Vet. Anaesth. Analg.201643217918810.1111/vaa.12296 26267292
     [Google Scholar]
  56. Centers for Disease Control and PreventionNew analysis looks at drug overdose deaths involving xylazine.Available From: https://blogs.cdc.gov/nchs/2023/06/30/7408/#:~:text=Key%20Findings%3A& (Accessed 4th December, 2023).
  57. ForresterM.B. Xylazine exposures reported to texas poison centers.J. Emerg. Med.201651438939310.1016/j.jemermed.2015.09.051 27473444
     [Google Scholar]
  58. Drug Enforcement Administration (DEA)DEA Joint Intelligence Report the Growing Threat of Xylazine and Its Mixture with Illicit Drugs.Available From: https://www.dea.gov/sites/default/files/2022-12/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf (Accessed 13th December, 2023).2022
  59. The Centre for Forensic Science Research & Education (CFSRE)Toxic Adulterant Alert: Medetomidine/Dexmedetomidine.Available From: https://www.cfsre.org/nps- discovery/public-alerts (Accessed on December 13, 2023).2023
  60. Witkowska-PiłaszewiczO. PingwaraR. SzczepaniakJ. WinnickaA. The effect of the clenbuterol-β2-adrenergic receptor agonist on the peripheral blood mononuclear cells proliferation, phenotype, functions, and reactive oxygen species production in race horses in vitro.Cells202110493610.3390/cells10040936 33920705
     [Google Scholar]
  61. WingertW.E. MundyL.A. NelsonL. WongS.C. CurtisJ. Detection of clenbuterol in heroin users in twelve postmortem cases at the Philadelphia medical examiner’s office.J. Anal. Toxicol.200832752252810.1093/jat/32.7.522 18713522
     [Google Scholar]
  62. LustE.B. BartholdC. MaleskerM.A. WichmanT.O. Human health hazards of veterinary medications: information for emergency departments.J. Emerg. Med.201140219820710.1016/j.jemermed.2009.09.026 20045604
     [Google Scholar]
  63. MoriartyN. AttarN. Clenbuterol-induced myocarditis: A case report.Eur. J. Case Rep. Intern. Med.202079001662 32908823
     [Google Scholar]
  64. National Institute on Drug Abuse (NIDA)Drugs, Brain, and Behaviour: The Science of Addiction - Drugs and the Brain. National Institute on Drug Abuse.Available from: https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drugs-brain#:~:text=pleasurable%20experience%2C%20a%20burst%20of (Accessed on 28th June, 2024).
  65. MilanoG. ChiappiniS. MattioliF. MartelliA. SchifanoF. β‐2 agonists as misusing drugs? assessment of both clenbuterol‐ and salbutamol‐related European medicines agency pharmacovigilance database reports.Basic Clin. Pharmacol. Toxicol.2018123218218710.1111/bcpt.12991 29498199
     [Google Scholar]
  66. BrettJ. DawsonA.H. BrownJ.A. Clenbuterol toxicity: A NSW poisons information centre experience.Med. J. Aust.2014200421922110.5694/mja13.10982 24580525
     [Google Scholar]
  67. SchifanoF. ChiappiniS. CorkeryJ. GuirguisA. Abuse of prescription drugs in the context of novel psychoactive substances (NPS): A systematic review.Brain Sci.2018847310.3390/brainsci8040073 29690558
     [Google Scholar]
  68. LinH.C. BransonK.R. ThurmonJ.C. BensonG.J. TranquilliW.J. OlsonW.A. Vähä-VaheA.T. Ketamine, Telazol, xylazine and detomidine. A comparative anesthetic drug combinations study in ponies.Acta Vet. Scand.199233210911510.1186/BF03547317 1502994
     [Google Scholar]
  69. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Polydrug Use: Patterns and ResponsesLuxembourg.Publications Office Eur. Union2009
     [Google Scholar]
  70. National crime intelligence service (NCIS). The United Kingdom threat assessment of serious organised crime.Trends Organ. Crime20031015257
     [Google Scholar]
  71. LeeC.C. LinY.Y. HsuC.W. ChuS.J. TsaiS.H. Movement disorder caused by abuse of veterinary anesthesia containing tiletamine.Am. J. Emerg. Med.20092781022.e51022.e610.1016/j.ajem.2008.12.030 19857439
     [Google Scholar]
  72. QuailM.T. WeimersheimerP. WoolfA.D. MagnaniB. Abuse of telazol: an animal tranquilizer.J. Toxicol. Clin. Toxicol.200139439940210.1081/CLT‑100105161 11527235
     [Google Scholar]
  73. ChungH. ChoiH. KimE. JinW. LeeH. YooY. A fatality due to injection of tiletamine and zolazepam.J. Anal. Toxicol.200024430530810.1093/jat/24.4.305 10872580
     [Google Scholar]
  74. de la PeñaJ.B.I. LeeH.C. de la PeñaI.C. WooT.S. YoonS.Y. LeeH.L. HanJ.S. LeeJ.I. ChoY.J. ShinC.Y. CheongJ.H. Rewarding and reinforcing effects of the NMDA receptor antagonist-benzodiazepine combination, Zoletil®: Difference between acute and repeated exposure.Behav. Brain Res.2012233243444210.1016/j.bbr.2012.05.038 22659394
     [Google Scholar]
  75. SmithR.C. MeltzerH.Y. AroraR.C. DavisJ.M. Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain.Biochem. Pharmacol.197726151435143910.1016/0006‑2952(77)90370‑7 901557
     [Google Scholar]
  76. TanK.R. RudolphU. LüscherC. Hooked on benzodiazepines: GABAA receptor subtypes and addiction.Trends Neurosci.201134418819710.1016/j.tins.2011.01.004 21353710
     [Google Scholar]
  77. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs.Available From: https://www.emcdda.europa.eu/publications/risk-assessments/ketamine_en (Accessed on 28th June, 2024).2002
     [Google Scholar]
  78. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)European Drug Report 2023: Trends and DevelopmentsAvailable From: https://www.emcdda.europa.eu/publications/european-drug-report/2023_en (Accessed on 28th June, 2024).2023
  79. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)European Drug ReportAvailable From: https://www.emcdda.europa.eu/publications/edr/trends-developments/2022_en (Accessed on 28th June, 2024).2022
     [Google Scholar]
  80. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)European Drug ReportAvailable From: https://www.emcdda.europa.eu/publications/edr/trends-develop-ments/2021_en (Accessed on 28th June, 2024).2021
     [Google Scholar]
  81. Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)Annual Report April 2022-March 2023.Available From: https://www.wedinos.org/reports-publications (Accessed on 28th June, 2024).2023
  82. Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)Annual Report 2021-2022.Available From: https://www.wedinos.org/reports-publications (Accessed on 28th June, 2024).2022
  83. Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)Annual Report 2020-2021.Available From: https://www.wedinos.org/reports-publications (Accessed on 28th June, 2024).2021
  84. Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)Annual Report 2019-2020.Available From: https://www.wedinos.org/reports-publications (Accessed on 28th June, 2024).2020
  85. Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)Annual Report 2018-2019.Available From: https://www.wedinos.org/reports-publications (Accessed on 28th June, 2024).2019
  86. Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)Annual Report 2017-2018.Available From: https://www.wedinos.org/reports-publications (Accessed on 28th June, 2024).2018
  87. Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)Annual Report 2016-2017.Available From: https://www.wedinos.org/reports-publications (Accessed on 28th June, 2024).2017
  88. Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)Annual Report 2015-2016.Available From: https://www.wedinos.org/reports-publications (Accessed on 28th June, 2024).2016
  89. LindeforsN. BaratiS. O’ConnorW.T. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex.Brain Res.1997759220521210.1016/S0006‑8993(97)00255‑2 9221938
     [Google Scholar]
  90. GaoM. RejaeiD. LiuH. Ketamine use in current clinical practice.Acta Pharmacol. Sin.201637786587210.1038/aps.2016.5 27018176
     [Google Scholar]
  91. GOV.UKUnited Kingdom drug situation 2019: Focal Point annual report.Available From: https://www.gov.uk/government/publications/united-kingdom-drug-situation-focal-point-annualreport/united-kingdom-drug- (Accessed on 10th December, 2023)2019
  92. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)New psychoactive substances: 25 years of early warning and response in Europe - an update from the EU Early Warning System.Available From: https://www.emcdda. europa.eu/publications/rapid-communication/update-eu- (Accessed on 28th June, 2024)
  93. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)The drug situation in Europe up to 2023 - an overview and assessment of emerging threats and new developments (European Drug Report 2023).Available From: https://www.emcdda.europa.eu/publications/european-drug-report/2023/drug-situation-in-europe-up-to-2023_en (Accessed 28th June, 2024)2023
     [Google Scholar]
  94. FrancescangeliJ. KaramchandaniK. PowellM. BonaviaA. The serotonin syndrome: From molecular mechanisms to clinical practice.Int. J. Mol. Sci.2019209228810.3390/ijms20092288 31075831
     [Google Scholar]
  95. LeeS.T. WuT.T. YuP.Y. ChenR.M. Apoptotic insults to human HepG2 cells induced by S-(+)-ketamine occurs through activation of a Bax-mitochondria-caspase protease pathway.Br. J. Anaesth.20091021808910.1093/bja/aen322 19001360
     [Google Scholar]
  96. BeertenS.G. MatheïC. AertgeertsB. Ketamine misuse: an update for primary care.Br. J. Gen. Pract.202373727878910.3399/bjgp23X731997 36702586
     [Google Scholar]
  97. Drug Enforcement Administration (DEA)DEA Releases 2016 Drug Threat Assessment: Fentanyl-Related Overdose Deaths Rising at an Alarming Rate.Available From: https://www.dea.gov/press-releases/2016/12/06/dea- (Accessed on 28th June, 2024).2016
  98. Van BeverW.F. NiemegeersC.J. SchellekensK.H. JanssenP.A. N-4-Substituted 1-(2-arylethyl)-4-piperidinyl-N-phenylpro-panamides, a novel series of extremely potent analgesics with unusually high safety margin.Arzneimittelforschung197626815481551 12771
     [Google Scholar]
  99. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)New psychoactive substances: global markets, global threats and the COVID- 19 pandemic - an update from the EU Early Warning System.Available From: https://www.emcdda.europa.eu/publications/rapid-communication/new- (Accessed on 28th June, 2024).
  100. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances.Available From: https://www.emcdda.europa.eu/publications/risk- assessments/carfentanil_en (Accessed on 28th June, 2024).
  101. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)EMCDDA-Europol Joint Report on a new psychoactive substance: methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)- amino]piperidine-4-carboxylate (carfentanil).Available From: https://www.emcdda.europa.eu/publications/joint-reports/carfentanil_en (Accessed on 28th June, 2024).
  102. PrekupecM.P. ManskyP.A. BaumannM.H. Misuse of novel synthetic opioids: A deadly new trend.J. Addict. Med.201711425626510.1097/ADM.0000000000000324 28590391
     [Google Scholar]
  103. WeiJ. LaiM. LiF. ChenY. LiX. QiuY. ShenH. XuP. DiB. Assessment of abuse potential of carfentanil.Addict. Biol.2023282e1326510.1111/adb.13265 36692872
     [Google Scholar]
  104. MiottoK. ChoA.K. KhalilM.A. BlancoK. SasakiJ.D. RawsonR. Trends in tramadol: Pharmacology, metabolism, and misuse.Anesth. Analg.20171241445110.1213/ANE.0000000000001683 27861439
     [Google Scholar]
  105. BabalonisS. LofwallM.R. NuzzoP.A. SiegelA.J. WalshS.L. Abuse liability and reinforcing efficacy of oral tramadol in humans.Drug Alcohol Depend.20131291-211612410.1016/j.drugalcdep.2012.09.018 23098678
     [Google Scholar]
  106. HeelR.C. BrogdenR.N. SpeightT.M. AveryG.S. Butorphanol.Drugs197816647350510.2165/00003495‑197816060‑00001 365510
     [Google Scholar]
  107. VotawV.R. GeyerR. RieselbachM.M. McHughR.K. The epidemiology of benzodiazepine misuse: A systematic review.Drug Alcohol Depend.20192009511410.1016/j.drugalcdep.2019.02.033 31121495
     [Google Scholar]
  108. JohnsonA.B. SadiqN.M. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Pentobarbital. 2025.
     [Google Scholar]
  109. The Centre for Forensic Science Research & Education (CFSRE)Sentinel Snapshot: Polydrug Counterfeit Fentanyl Tablets.Available from: https://www.cfsre.org/nps-discovery/public-alerts/sentinel-snapshot-polydrug- (Accessed on 19th March, 2024)
  110. AlgrenD.A. AshworthA. Acute acepromazine overdose: clinical effects and toxicokinetic evaluation.J. Med. Toxicol.201511112112310.1007/s13181‑014‑0416‑1 25059809
     [Google Scholar]
  111. ErramouspeJ. AdamcikB.A. CarlsonR.K. Veterinarian perception of the intentional misuse of veterinary medications in humans: a preliminary survey of Idaho-licensed practitioners.J. Rural Health200218231131810.1111/j.1748‑0361.2002.tb00893.x 12135152
     [Google Scholar]
  112. de LimaL.F. de AraujoW.R. A highly efficient and portable laser-scribed graphene-based electrochemical system for forensic-oriented determination of acepromazine.Anal. Methods202315354467447610.1039/D3AY00815K 37644817
     [Google Scholar]
  113. SchneidersF.I. NobleG.K. BostonR.C. DunstanA.J. SillenceM.N. McKinneyA.R. Acepromazine pharmacokinetics: A forensic perspective.Vet. J.20121941485410.1016/j.tvjl.2012.03.017 22534188
     [Google Scholar]
  114. KamathS.D. UpadhayaA. MehtaN. YadavP. Spectrum of toxicity due to pheniramine overuse in a COVID-19 patient. How much do we know?J. Family Med. Prim. Care202211127953795610.4103/jfmpc.jfmpc_853_22 36994041
     [Google Scholar]
  115. DinwiddieA.T. TanzL.J. BittingJ. Notes from the Field: Antihistamine positivity and involvement in drug overdose deaths — 44 Jurisdictions, United States, 2019-2020.MMWR Morb. Mortal. Wkly. Rep.202271411308131010.15585/mmwr.mm7141a4 36227774
     [Google Scholar]
  116. OyekanP.J. GortonH.C. CopelandC.S. Antihistamine‐related deaths in England: Are the high safety profiles of antihistamines leading to their unsafe use?Br. J. Clin. Pharmacol.202187103978398710.1111/bcp.14819 33729599
     [Google Scholar]
  117. BuckleyN.A. WhyteI.M. DawsonA.H. CruickshankD.A. Pheniramine - a much abused drug.Med. J. Aust.19951624171224
     [Google Scholar]
  118. GargS. TyagiP. TejanV. DhillonM. An unusual case of dependence of megadose of veterinary intravenous pheniramine with opioid use disorder.Indian J. Pharmacol.202254214814910.4103/ijp.ijp_868_21 35546468
     [Google Scholar]
  119. Pons-HernandezM. WyattT. HallA. Investigating the illicit market in veterinary medicines: An exploratory online study with pet owners in the United Kingdom.Trends Organ. Crime202226121 36097496
     [Google Scholar]
  120. Home OfficeList of most commonly encountered drugs currently controlled under the misuse of drugs legislation.Available From: https://www.gov.uk/government/publications/controlled-drugs-list--2/list-of- (Accessed 19th December, 2023).
  121. OzcagliE. KaraM. KotilT. FragkiadakiP. TzatzarakisM. TsitsimpikouC. StivaktakisP. TsoukalasD. SpandidosD. TsatsakisA. AlpertungaB. Stanozolol administration combined with exercise leads to decreased telomerase activity possibly associated with liver aging.Int. J. Mol. Med.201842140541310.3892/ijmm.2018.3644 29717770
     [Google Scholar]
  122. KanayamaG. HudsonJ.I. PopeH.G. Jr Illicit anabolic-androgenic steroid use.Horm. Behav.201058111112110.1016/j.yhbeh.2009.09.006 19769977
     [Google Scholar]
  123. KanayamaG. BrowerK.J. WoodR.I. HudsonJ.I. PopeH.G.Jr Anabolic-androgenic steroid dependence: an emerging disorder.Addiction2009104121966197810.1111/j.1360‑0443.2009.02734.x 19922565
     [Google Scholar]
  124. CadwalladerA.B. De La TorreX. TieriA. BotrèF. The abuse of diuretics as performance‐enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis.Br. J. Pharmacol.2010161111610.1111/j.1476‑5381.2010.00789.x 20718736
     [Google Scholar]
  125. CohenM.J. HanburyR. StimmelB. Abuse of amitriptyline.JAMA1978240131372137310.1001/jama.1978.03290130066024 682328
     [Google Scholar]
  126. UmaharanT. SivayokanS. SivansuthanS. Amitriptyline dependence and its associations: A case report and literature review.Case Rep. Psychiatry202120211310.1155/2021/6647952 33564485
     [Google Scholar]
  127. American Veterinary Medical Association (AVMA)FDA warns Micotil300 is dangerous.Available from: https://www.avma.org/javma-news/2017-11-15/fda-warns-micotil-300-dangerous (Accessed on 21st March, 2024).
  128. LajtaiA. MayerM. LakatosÁ. PorpáczyZ. MisetaA. Embutramide, a component of Tanax® (T‐61) as a new drug of abuse?J. Forensic Sci.201661257357510.1111/1556‑4029.13010 27404634
     [Google Scholar]
  129. The Centre for Forensic Science Research & Education (CFSRE)Phenylbutazone: A Toxic Adulterant Found in Illicit Street Drugs.Available from: https://www.cfsre.org/images/content/reports/public_alerts/Phenylbutazone_Public_Health_Alert_031323_final.pdf (Accessed on 28th June, 2024).
     [Google Scholar]
  130. HudsonS. The misuse of over-the-counter NSAIDs.BU Well201941
     [Google Scholar]
  131. WiegandT.J. Adulterated cocaine and lessons learned from the Jake walk blues.J. Med. Toxicol.201061636610.1007/s13181‑010‑0010‑0 20221861
     [Google Scholar]
  132. FiorentinT.R. KrotulskiA.J. MartinD.M. BrowneT. TriplettJ. ContiT. LoganB.K. Detection of cutting agents in drug‐positive seized exhibits within the United States.J. Forensic Sci.201964388889610.1111/1556‑4029.13968 30485426
     [Google Scholar]
  133. RonsoniM.F. SantosH.C. ColomboB.S. CorreaC.G. MoritzA.P.G. CoralM.H.C. Sande-LeeS.V. HohlA. Hypercalcemia and acute renal insufficiency following use of a veterinary supplement.J. Bras. Nefrol.201739446746910.5935/0101‑2800.20170082 29319776
     [Google Scholar]
  134. De Francesco DaherE. Mesquita MartinianoL.V. Lopes LimaL.L. Viana Leite FilhoN.C. de Oliveira SouzaL.E. Duarte FernandesP.H.P. da SilvaS.L. da Silva JuniorG.B. Acute kidney injury due to excessive and prolonged intramuscular injection of veterinary supplements containing vitamins A, D and E: A series of 16 cases.Nefrología2017371616710.1016/j.nefro.2016.05.017 27577045
     [Google Scholar]
  135. RochaP.N. SantosC.S. AvilaM.O. NevesC.L. Hypercalcemia and acute kidney injury caused by abuse of a parenteral veterinary compound containing vitamins A, D and E.Braz. J. Nephrol.201133446747110.1590/S0101‑28002011000400013
     [Google Scholar]
  136. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).Available from: https://www.emcdda.europa.eu/publications/data-factsheet/syringe-residues-analysis-data-escapeproject_en (Accessed on 11th December, 2023).
  137. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).Available from: https://www.emcdda.europa.eu/publications/eu-drug-markets/heroin-and-other-opioids/retailmarkets_en (Accessed 31st May, 2024).
/content/journals/cn/10.2174/011570159X333443240822115028
Loading
Exploring the Confluence of Animal Medicine and its Implications for Human Health: A Systematic Literature Review
Curr. Neuropharmacol. 23, 847 (2025); https://doi.org/10.2174/011570159X333443240822115028
/content/journals/cn/10.2174/011570159X333443240822115028
/content/journals/cn/10.2174/011570159X333443240822115028
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): animal medicines; diversion of medicines; drug misuse; self-medication; substance use; Veterinary medicines

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test